Latest Breaking News On - Alanj kivitz - Page 1 : vimarsana.com

IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA

Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy vs placebo in treating psoriatic arthritis and axial spondyloarthritis.

Alan J. Kivitz, MD: Phase 2b Data on TAK-279 for Psoriatic Arthritis

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

Alan J. Kivitz, MD: Next Steps for Research on TAK-279 for Psoriatic Arthritis

This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis.

Prometheus Laboratories Announces Collaboration with Fresenius Kabi on Anser Testing

Prometheus Laboratories Announces Collaboration with Fresenius Kabi on Anser Testing